Ambroxol to Slow Parkinson’s Disease Progression
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial studies whether ambroxol (or a placebo) can slow the progression of Parkinson’s disease. It may help by aiming to change how the disease develops over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’ve been diagnosed with Parkinson’s disease within the last 7 years.
- You are between 35 and 75 years old.
- Your Parkinson’s symptoms are in an early-to-moderate stage (Hoehn and Yahr 1 to 2.5 while on your usual “ON” medication).
- Your genetic test results for GBA1 are known (positive or negative) before screening.
- You can take your Parkinson’s medicines steadily for at least 3 months before joining, and you can reliably swallow and self-take the study pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests a remote way to assess people newly diagnosed with Parkinson's disease, to help monitor their condition and guide care.
This trial looks at ambroxol, a medicine, for people who have Gaucher disease and Parkinson disease that is linked to Gaucher. If you fit the condition group, the study may help doctors learn whether ambroxol can improve Parkinson-related symptoms in this specific situation.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.